Development And Manufacturing Of Biologics
We are interested to speak with multiple experts from cdmos (contract development and manufacturing organization) who can discuss the market for contract manufacturing of biologics in the us and europe.
This is a 1-hour paid phone interview. Kindly respond to the questions below with a brief explanation as to your relevance in this space.
1. Can you discuss the total size of the market for contract manufacturing of biologics?
2. Are you able to share your insights in the cdmo partner selection criteria?
**please note that we are only interested in your expert opinion and are not seeking any confidential information.
+44 Other ResponsesPharmaceutical Raw Materials
***this is a resend. We are urgently seeking to speak with multiple experts knowledgeable about this topic. Note: zintro is paying a referral fee if you forward this to another expert knowledgeable in this area.***
we are a large multinational firm looking to better understand the following as it relates to cgmp (current good manufacturing practices) vaccine manufacturing raw material costs:
1. What would be typical raw material costs per dose of a liquid vaccine? By what factor would it be higher for lyophilized bulk?
2. What would be the major cost contributors to raw materials?
3. Are these the same for single antigen/ multi-antigen vaccines per unit? If not, what factor would apply to the multi-antigen vaccine? Would a factor of 4x be appropriate for a pentavalent vaccine compared to a single-valent vaccine?
4. Do the cost of these differ if manufactured in us/ europe or india? We are considering a factor of 2 for procurement abroad, would this be a fair assumption? Why would there be such a variance?
5. Would costs vary if the material is sourced from different countries? What country suppliers supply material at lower rates? Comparatively at what multiple is the cost for the suppliers offering highest quality material?
6. What components of raw materials are commodities and do not differ in cost across the world?
7. Would the raw material costs vary if procured in small quantities versus large quantities? What multiple can we consider for small volume players compared to large volume players?
8. Are there any losses associated with blending multiple antigens? Would 0.05 cents per dose be an appropriate figure?
9. Compared to the pentavalent vaccine would rota, ipv, hpv, pneumococcal vaccines have higher rm costs? What could be the reasons for such a hike in cost and by how much would the cost be higher?
10. Is there an additional rm cost due to loss of antigen for sensitive antigens like ipv?
11. What factor should we consider to account for the learning curve? What would be the initial rm costs to say 3 – 5 years down the line? Is it half or 10%? What drives this? Is it because of yield losses? Any there any other factors.
12. In summary, what be the average raw material cost differences between those for simple versus complex vaccines?
*please describe your relevant expertise and attach your cv. Thank you.
+21 Other Responses
